The closing price of Agilon Health Inc (NYSE: AGL) was $4.75 for the day, down -1.86% from the previous closing price of $4.84. In other words, the price has decreased by -$0.0900 from its previous closing price. On the day, 2714146 shares were traded.
Ratios:
Our analysis of AGL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.51 and its Current Ratio is at 1.51. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on March 06, 2024, initiated with a Underweight rating and assigned the stock a target price of $5.
On February 26, 2024, TD Cowen Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $12 to $6.50.
Jefferies Downgraded its Buy to Hold on February 26, 2024, whereas the target price for the stock was revised from $25 to $6.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 29 ’23 when Schwaneke Jeffrey A. bought 22,300 shares for $11.22 per share. The transaction valued at 250,206 led to the insider holds 31,931 shares of the business.
Shaker Benjamin sold 18,750 shares of AGL for $337,455 on Sep 13 ’23. The Chief Markets Officer now owns 79,543 shares after completing the transaction at $18.00 per share. On Sep 12 ’23, another insider, Shaker Benjamin, who serves as the Chief Markets Officer of the company, sold 18,750 shares for $18.05 each. As a result, the insider received 338,481 and left with 79,543 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGL now has a Market Capitalization of 1.95B and an Enterprise Value of 1.51B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.43 while its Price-to-Book (P/B) ratio in mrq is 2.92. Its current Enterprise Value per Revenue stands at 0.35 whereas that against EBITDA is -8.99.
Stock Price History:
Over the past 52 weeks, AGL has reached a high of $28.99, while it has fallen to a 52-week low of $4.44. The 50-Day Moving Average of the stock is 5.9398, while the 200-Day Moving Average is calculated to be 13.0897.
Shares Statistics:
AGL traded an average of 6.25M shares per day over the past three months and 4.99M shares per day over the past ten days. A total of 406.39M shares are outstanding, with a floating share count of 302.58M. Insiders hold about 26.12% of the company’s shares, while institutions hold 85.77% stake in the company. Shares short for AGL as of Mar 15, 2024 were 46.96M with a Short Ratio of 7.52, compared to 46.12M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.47% and a Short% of Float of 39.64%.
Earnings Estimates
The firm’s stock currently is rated by 10 analysts. On average, analysts expect EPS of -$0.01 for the current quarter, with a high estimate of $0.09 and a low estimate of -$0.08, while EPS last year was $0.04. The consensus estimate for the next quarter is -$0.05, with high estimates of $0.02 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.06 and -$0.52 for the fiscal current year, implying an average EPS of -$0.3. EPS for the following year is -$0.18, with 11 analysts recommending between $0.2 and -$0.46.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 15 analysts. It ranges from a high estimate of $1.63B to a low estimate of $1.47B. As of the current estimate, Agilon Health Inc’s year-ago sales were $1.14B, an estimated increase of 41.00% from the year-ago figure. For the next quarter, 15 analysts are estimating revenue of $1.6B, an increase of 39.30% less than the figure of $41.00% in the same quarter last year. There is a high estimate of $1.63B for the next quarter, whereas the lowest estimate is $1.51B.
A total of 16 analysts have provided revenue estimates for AGL’s current fiscal year. The highest revenue estimate was $6.47B, while the lowest revenue estimate was $6.1B, resulting in an average revenue estimate of $6.39B. In the same quarter a year ago, actual revenue was $4.32B, up 48.10% from the average estimate. Based on 16 analysts’ estimates, the company’s revenue will be $7.99B in the next fiscal year. The high estimate is $8.6B and the low estimate is $7.55B. The average revenue growth estimate for next year is up 24.90% from the average revenue estimate for this year.
